AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06352749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Physical Exercise
Description: This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised online by trained physiotherapists or sports physiologists.
Study NCT06352749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face Exercise
Description: This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised face-to-face by trained physiotherapists or sports physiologists.
Study NCT04985318 — intervention group
Intervention type: DRUG
Intervention: Cablivi®
Description: Intervention with Cablivi® take place outside of the study
Study NCT05142462 — intervention group
Intervention type: DEVICE
Intervention: Hip arthroplasty
Description: Hip prosthesis surgical implantation
Study NCT06191757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supported with the developmental support program
Description: Babies were developmentally supported with the developmental support program
Study NCT05548270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Study NCT05548270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Study NCT05879614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Study NCT05297604 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vascular photobiomodulation (VPBM)
Description: The participants received a 20-minute single session of VPBM. This noninvasive method involves the use of low-power laser coupled to a bracelet designed to transport the light beam transcutaneously over the radial artery. The laser device (DMC Therapy Ec) delivered irradiation with a power of 100 ± 20 mW, wavelength of 660 ± 10 nm (red light) and energy of 120 J applied continuously, with irradiance of 35 W/cm².
Study NCT05297604 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Sham group (simulated vascular photobiomodulation)
Description: Simulated radiation. The participants received a single session.
Study NCT06068790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 French sized rigid sheath
Description: The 28Fr is the standard of care sheath size used at this site.
Study NCT06068790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 French sized rigid sheath
Description: The 22Fr is the smaller, investigational sheath size to be used in this study.
Study NCT05227404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LumiraDX
Description: Point-of-care test for SARS-CoV-2
Study NCT05227404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RightSign
Description: Point-of-care test for SARS-CoV-2
Study NCT05227404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Case Control
Description: Genscript assay performed on the plasma sample
Study NCT05980585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM Device
Description: Daily use of the CPM wearable device
Study NCT06346015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Entrainment Stimulation
Description: Audio-assisted therapy: receive audio therapy with a specific device for 30 minutes, once in the morning and evening for 3 months.~(Binaural beat treatment group: receive binaural beat treatment with a specific device for 30 minutes, once in the morning and evening, for 3 months.）
Study NCT05638646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
Study NCT05638646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Maintain current treatment
Study NCT05859295 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Red Low-Level Light Therapy
Description: Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
Study NCT05130203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MouvMat Exergaming
Description: Sessions engaging with exergaming device.
Study NCT05130203 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Recreational Programming
Description: Conducted by recreational therapists.
Study NCT05178602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Intervention Group
Description: Tai Chi intervention group: routine treatment and tai Chi exercise,5 times a week.
Study NCT06079021 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb
Description: Application of CytoSorb treatment for 72 hours in patients with ACLF
Study NCT04872660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gushen Antai Pill
Description: The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
Study NCT04872660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
Study NCT05737654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with augmented reality glasses
Description: Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
Study NCT06580002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Given PO
Study NCT06580002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT05821166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moderate Whole Body Hyperthermia (mWBH)
Description: Patients receiving 3-4 times mWBH
Study NCT06366191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prevention algorithm
Description: a health watch adapted to stress and dissociative symptoms
Study NCT06366191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for post traumatic stress disorder
Study NCT05385003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: anserine
Description: During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
Study NCT04711031 — intervention group
Intervention type: OTHER
Intervention: FLUS
Description: The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
Study NCT06582290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oxford Virtual Autism Assessment Tool (OVAAT)
Description: The OVAAT is an online ASD diagnostic tool that has been designed to identify both the external/observable features of autism but also the internal/experiential features of autism.
Study NCT06583200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: End Expiratory Occlusion Test
Description: All studied mechanically ventilated patients under post operative sedation. EEO test will be applied to predict probable responder and probable non-responder according to pulse pressure variation in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of 5% or more
Study NCT06583200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Passive Leg Raising Test
Description: All studied mechanically ventilated patients under post operative sedation.Passive leg raising test will be applied to predict probable responder and probable non-responder according to the PPV in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of at least 10%
Study NCT05609656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use.
Study NCT05609656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved.
Study NCT05609656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor).
Study NCT04916132 — intervention group
Intervention type: PROCEDURE
Intervention: Kidney Biopsy
Description: Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
Study NCT06066242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different induction chemotherapy regimens
Description: azacitidine combined with venetoclax or chemotherapy with or without venetoclax
Study NCT06498570 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intracorneal rings
Description: The (ICRS), intracorneal rings segments implantation surgery
Study NCT05385003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower peptide
Description: During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
Study NCT05385003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
Study NCT04275973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower limb prostheses
Description: Standard commercially available prostheses for participants with lower-limb amputation.~Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA).
Study NCT06581445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birdsongs
Description: The participants listened to a clip of birdsongs from laughing thrushes.
Study NCT06581445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: The participants listened to a cheerful Cuckoo Waltz music.
Study NCT04275973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthoses for Drop-foot
Description: Standard commercially-available orthoses or standard-of-care custom orthoses as well as standard commercially-available electrical stimulation neuro-orthoses.
Study NCT04275973 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Footwear
Description: Different footwear will be used.
Study NCT05416879 — intervention group
Intervention type: DEVICE
Intervention: Actigraph GT3X+BT
Description: 7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
Study NCT01201278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
Study NCT01201278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
Study NCT01201278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Subcutaneous insulin lispro 8 U
Study NCT06366763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (CIVIQ-14 and VCSS scores )
Study NCT05969535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth preparation education according to travelbee human-human relations theory
Description: human-to-human communication and psychoeducation-assisted birth preparation training
Study NCT05997420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR Program
Description: In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
Study NCT05997420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
Study NCT06186063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
Study NCT06186063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline) infusion
Description: At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
Study NCT05264506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 COC
Description: Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed.
Study NCT06169982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC
Study NCT06126341 — intervention group
Intervention type: OTHER
Intervention: Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM
Description: Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.
Study NCT06126341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Hospital Anxiety and Depression Scale
Description: Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire
Study NCT06126341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Duke-UNC Functional Social Support Questionnaire
Description: A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.
Study NCT06126341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Distress Thermometer
Description: The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress
Study NCT06126341 — intervention group
Intervention type: BEHAVIORAL
Intervention: FACT-BMT
Description: The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
Study NCT05957822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA
Description: Tranexamic acid injection 8-10mg/kg
Study NCT05957822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA
Description: Tranexamic acid injection 8-10mg/kg
Study NCT05957822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TEG6
Description: performing thromboelastography (TEG6)
Study NCT05786768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single infusion of Rituximab
Description: single infusion of Rituximab 375 mg/m2
Study NCT05786768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single infusion of Obinutuzumab
Description: single infusion of Obinutuzumab 300mg/1.73 m2
Study NCT00925327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking with riboflavin/UVA light
Description: Corneal collagen cross-linking with riboflavin/UVA light
Study NCT05697276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
Study NCT05697276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
Study NCT05225701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic guided internet-delivered intervention with synchronous assistance
Description: Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.